Brent Kleintop

Articles by Brent Kleintop

Perspectives on Quality Attributes of Drug Products Containing Nanomaterials

ByKahkashan Zaidi, PhD,Brent Kleintop,John Hammond,Nancy Lewen,Emmanuel Akala,Anthony Hickey,Jolyon Mitchell,June Liang,Timothy Shelbourn,Katherine Tyner,Eloise Welfare,Norbert Maurer,Munir Hussain,Lawrence Block,Myke Scoggins,Thomas Tice

October 1st 2019

In this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.

GMPs for Method Validation in Early Development: An Industry Perspective (Part II)

ByBrent Kleintop,Mark D. Trone,Michael Szulc,Donald Chambers,Kristin Patterson,Gary Guo,Henrik Rasmussen,Steve Deegan,John Spicuzza,Steven Nowak,Zhanna Yuabova,Karla Tombaugh

July 2nd 2012

IQ Consortium representatives explore industry approaches for applying GMPs in early development.

GMPs for Small-Molecule Drugs in Early Development (Part I)

ByTony Mazzeo,Amnon Eylath,John W. Skoug,Brent Kleintop,Andy Rignall,James S. McElvain

June 2nd 2012

IQ Consortium representatives explore and define common industry approaches and practices for applying GMPs in early development.

Latest Updated Articles

GMPs for Method Validation in Early Development: An Industry Perspective (Part II)
Published: July 2nd 2012 | Updated:
GMPs for Small-Molecule Drugs in Early Development (Part I)
Published: June 2nd 2012 | Updated:
Perspectives on Quality Attributes of Drug Products Containing Nanomaterials
Published: October 1st 2019 | Updated: